← Back to Search

Pembrolizumab for Small Cell Carcinoma of Ovary (Pemb-HT Trial)

N/A

Waitlist Available

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Pemb-HT Trial Summary

This trial is testing pembrolizumab to see if it can help treat patients with small cell carcinoma of the ovary, hypercalcemic type.

Who is the study for?

This trial is specifically for patients who have been diagnosed with a rare type of ovarian cancer known as small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). There are no listed exclusion criteria, suggesting it may be open to a wide range of people with this condition.Check my eligibility

What is being tested?

The study is testing pembrolizumab as an additional treatment after initial therapy for SCCOHT. Pembrolizumab is an immunotherapy drug that helps the immune system fight cancer cells.See study design

What are the potential side effects?

Pembrolizumab can cause side effects like fatigue, cough, nausea, itching, skin rash, loss of appetite and diarrhea. It might also lead to more serious conditions involving the lungs, intestines or liver.

Pemb-HT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Progression free survival

Secondary outcome measures

Exploratory Endpoint

Objective evidence of response to treatment

overall performance status

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183

21%

Fatigue

13%

Nausea

11%

Back pain

Shortness of Breath

Anemia

Abdominal pain

Diarrhea

Pneumonia

Kidney Injury and/or Infection

Dyspnea

Weight Loss

Malnutrition, Hypercalcemia and Weakness

Pneumothorax

Intractable pain, back pain, hip pain

Activated partial thromboplastin time prolonged

Pleural effusion

Atrial fibrillation with rapid ventricular response

Thrombocytopenia

Respiratory failure

Skin rash

colitis

100%

80%

60%

40%

20%

Study treatment Arm

Single Arm

Pemb-HT Trial Design

1Treatment groups

Experimental Treatment

Group I: PembrolizumabExperimental Treatment1 Intervention

Pembrolizumab will be given as an intravenous infusion at 200 mg, every 6 weeks, for 6 cycles.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

2017

Completed Phase 2

~2010

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,471 Previous Clinical Trials

484,969 Total Patients Enrolled

14 Trials studying Ovarian Cancer

3,482 Patients Enrolled for Ovarian Cancer

Media Library

Pembrolizumab Clinical Trial Eligibility Overview. Trial Name: NCT05368207 — N/A

Ovarian Cancer Research Study Groups: Pembrolizumab

Ovarian Cancer Clinical Trial 2023: Pembrolizumab Highlights & Side Effects. Trial Name: NCT05368207 — N/A

Pembrolizumab 2023 Treatment Timeline for Medical Study. Trial Name: NCT05368207 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the enrollment period for this experiment still active?

"According to clinicaltrials.gov, this trial is not presently recruiting patients despite its initial posting on December 6th 2021 and recent update on May 9th 2022. Nevertheless, there are 3227 alternative studies that require new participants at the moment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient

2021. "Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05368207.